American BriVision (Holding) Corporation



PE Ratio
Market Cap
52 Week Range
$1.80 - $6.75
Operating Margin
Dividend & Yield
$0.00 (0.00%)
Rev. per Share

About American BriVision (Holding) Corporation

American BriVision (Holding) Corporation, a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, a combination therapy for triple negative breast cancer; ABV-1504 for major depressive disorders; ABV-1505 for attention deficit hyperactivity disorder; ABV-1703 for the treatment of pancreatic cancer; ABV-1702 to treat myelodysplastic syndromes; and ABV-1601 for treating depression in cancer patients. It has a co-development agreement with Rgene Corporation; collaboration agreement with BioHopeKing Corporation to develop ABV-1501; and collaborative agreement with BioFirst Corporation to co-develop BFC-1401 vitreous substitute for Vitrectom; and license with BioFirst Corporation to research and develop a medical device, ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. The company was founded in 2015 and is based in Fremont, California. American BriVision (Holding) Corporation is a subsidiary of YuanGene Corporation.


News about American BriVision (Holding) Corporation

American BriVision (Holding) Corporation

About kinfo
Kinfo is an app for DIY traders and investors. Kinfo tracks your trading performance and lets you compare measurable performance metrics against other traders. Kinfo works for day trading, swing trading and longer holding periods. By tracking portfolio performance kinfo allows traders to learn, find inspiration and gain confidence.
Get Social
Download the App